ESHAP versus rituximab-ESHAP in frail patients with refractory diffuse large B-Cell lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 2, 2010, Pages 125-128

  Avilés, Agustin ^a   Neri, Natividad ^a   Huerta Guzmán, Judith ^a   De Jesus Nambo, María ^a  

^a HOSPITAL DE ONCOLOGÍA   (Mexico)

Author keywords

Cytosine arabinoside; Etoposide; Granulocytopenia; Methylprednisolone; Platinum; Rituximab

Indexed keywords

ACICLOVIR; CYTARABINE; ETOPOSIDE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; PLATINUM; RITUXIMAB; ANTINEOPLASTIC AGENT; CISPLATIN; COLONY STIMULATING FACTOR; ESAP PROTOCOL; MONOCLONAL ANTIBODY;

ANEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HERPES ZOSTER; HUMAN; HUMAN PARVOVIRUS B19; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS JIROVECI; PNEUMONIA; PROGRESSION FREE SURVIVAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEPTICEMIA; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VOMITING; ADULT; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG TOLERANCE; FRAIL ELDERLY; KLEBSIELLA INFECTION; NAUSEA AND VOMITING; PARVOVIRUS INFECTION; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS INFECTION; STATISTICAL ANALYSIS; STREPTOCOCCUS INFECTION; URINARY TRACT INFECTION; B CELL LYMPHOMA; B LYMPHOCYTE; DISEASE FREE SURVIVAL; LYMPHOMA; MIDDLE AGED; REMISSION;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; CISPLATIN; COLONY-STIMULATING FACTORS; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; METHYLPREDNISOLONE; MIDDLE AGED; REMISSION INDUCTION;

EID: 77954682208     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.017     Document Type: Article

References (24)

1. Sehadni T, Kuruvilla J, Crump M, et al. Salvage therapy for relapsed/refractory diffuse large B-Cell lymphoma. Biol Blood Marrow Transplant 2008;14:259-67.
2. Prichard M, Harris T, Williams ME, et al. Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma. Expert Opin Pharmacother 2009;10:983-95.
3. Buser AS, Stern M, Bucher C et al. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogenic ste,-cell transplantation for refractory or relapsing lymphomas. Bone Marrow Tranpl 2007;39:335-40.
4. Avilés A, Neri N, Huerta-Guzman J, et al. Gemcitabine and cisplatin in refractory malignant lymphoma. Oncology 2004;66:197-200.
5. Jo JC, Kang KW, Jarg G et al. BEAC or BEAM high-dose chemotherapy followed by autologous cell transplantation in non-Hodgkin's lymphoma patients. Ann Hematol 2008;87:43-8.
6. Crump M, Baetz T, Corban S et al. Gemcitabine, dexamethasone and cisplatin in patients with recurrent or refractory aggressive histology B-Cell non-Hodgkin's lymphoma. Cancer 2004;101:1835-42.
7. Press OW, Livingstone R, Mortimer J, et al. Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high dose cytarabine and cisplatin before marrow transplantation. J Clin Oncol 1991;5:423-31.
8. Haim N, Ben-Shahar M, Farraci D, et al. Dexamethasone, etoposide, ifosfamide and cisplatin as secondary therapy in patients with aggressive non-Hodgkin's lymphoma. Cancer 1997;80:1989-96.
9. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma lymphoma with cisplatin and high-dose Ara C and dexamethasone (DHAP). Blood 1988;71:117-22.
10. Velasquez WS, McLaughlin P, Tucker S et al. ESHAP an effective chemotherapy regimen in refractory and relapsing lymphoma. J Clin Oncol 1994;12:1169-76.
11. Martelli M, Vigneti M, Zinzanin PL et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin and cy-tarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy. J Clin Oncol 1996;14:534-42.
12. Harting R, Venugopal P, Gregory SA, et al. Efficacy and safety of Rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-Cell non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2007;7:406-12.
13. Kewalramani T, Zeleneiz AD, Nimer SD et al. Rituximab and ICE as second line therapy before autologous stem cell transplantation for relapsed or refractory diffuse large B-Cell lymphoma. Blood 2004;103:3684-8.
14. Corazelli G, Russo F, Capoblanco G et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX) a new effective cytoreduction /mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2006;17(suppl 4):18-24.
15. Witzig TE, Geyer SM, Kurtin PJ et al. Salvage chemotherapy with rituximab for relapsed non-Hodgkin's lymphoma. Leuk Lymphoma 2008;49:1074-8.
16. Sieawski M, Staak U, Glossman JP et al. Rituximab added to interfiled salvage chemotherapy program followed by autologous stem cell transplantation improves the outcome in relapsed and refractory aggressive non-Hodgkin's lymphoma. Ann Hematol 2007;86:106-11.
17. Hagberg H, Gisselbrecht C. Randomized Phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-Cell lymphoma followed by high-dose therapy and second randomization to maintenance treatment with rituximab or not. Ann Oncol 2006;17(suppl 4):31-2.
18. Lugtenburg PJ, Sonneveled P. Treatment of diffuse large B-Cell lymphoma in the elderly. Curr Opin Oncol 2008;10:412-9.
19. Cheson BD, Horning S, Coiffier B et al. Report of an Internationa Workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:1244-53.
20. Aksoy S, Harputluoglu H, Klickap S et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307-12.
21. Ram R, Ben-Bassat I, Shpilberg O, et al. The late adverse events of rituximab therapy-rare but there. Leuk Lymphoma 2009;50:1083-95.
22. Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-Cell lymphoma: the influence or prior exposure to rituximab on outcome. Haematologica 2008;93:1829-36.
23. Lugtenburg PJ, Sonnenveld P. Treatment of diffuse large B-Cell lymphoma in the elderly. Strategies integrating oncogeriatric themes. Curr Oncol Rep 2008;10:412-9.
24. Soubeyran P, Mertens C, Bellera C, et al. Management of unfit patients with unfavourable non-Hodgkin's lymphomas. Cancer Treat Rev 2009;25:528-32.